Diabetes Care, Vol 23, Issue 10 1551-1555, Copyright © 2000 by American Diabetes Association
Systemic hyperbaric oxygen therapy: lower-extremity wound healing and the diabetic foot
RP Wunderlich, EJ Peters and LA Lavery
Diabetex Foot Care Center, San Antonio, Texas 78212, USA. robert@wunderlich.com
OBJECTIVE: To document peer-reviewed medical publications that have
reported on hyperbaric oxygen (HBO) therapy as an adjunct to standard
lower-extremity wound care, focusing on publications dealing with the
diabetic foot. RESEARCH DESIGN AND METHODS: A review of the medical
literature was conducted using MEDLINE. Research articles involving HBO
treatment and the diabetic foot were critiqued to identify factors that may
have been a source of bias. RESULTS: Of the published reports on human
studies, seven involved diabetes-related foot pathology. Five of these
studies, two of which were randomized, included a control group that did
not receive HBO therapy The controlled diabetic foot studies included an
average of 28 subjects in the HBO therapy group (range 10-62) and an
average of 16.2 subjects in the non-HBO control group (range 5-33). Most of
the published reports have several potential sources of bias, including,
but not limited to, inadequate evaluation of comorbid conditions relevant
to wound healing, small sample size, and poor documentation of wound size
or severity. Four of the seven reports involving the diabetic foot were
published by a group of researchers at the University of Milan between 1987
and 1996. CONCLUSIONS: Additional randomized placebo-controlled clinical
trials in large diabetic populations would further lend credence to the
presumption that HBO therapy improves clinical outcomes. Given the
relatively high cost of this treatment modality, perhaps a more acute
awareness of the medical literature would reduce the economic burden that
HBO therapy imposes on care providers that are financially at risk.